NVO vs OMDA
NVO: A global leader in chronic disease treatment, particularly diabetes, focused on scientific innovation and patient access. OMDA: Virtual care platform combining human health coaches and AI-driven technology to deliver preventive and chronic disease management programs for cardiometabolic conditions, obesity, and musculoskeletal health at scale.
Side-by-side fundamentals
| Metric | NVO | OMDA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $49.67 | $20.58 | |
| Market cap as of 2026-07-31 | $228.2B | $1.2B | |
| P/E as of 2026-07-31 | 12.29 | n/a | |
| PEG as of 2026-07-31 | 16.16 | n/a | |
| Net margin as of 2026-07-31 | +37.2% | -2.2% | NVO higher |
| Gross margin as of 2026-07-31 | +81.8% | +66.3% | NVO higher |
| Operating margin as of 2026-07-31 | +45.3% | -3.7% | NVO higher |
| ROE as of 2026-07-31 | +66.4% | -2.8% | NVO higher |
| ROA as of 2026-07-31 | +23.3% | -2.1% | NVO higher |
| Debt / equity as of 2026-07-31 | 0.72 | 0.00 | OMDA lower |
| Revenue growth (YoY) as of 2026-07-31 | +8.1% | +42.0% | OMDA higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +45.6% | |
| Dividend yield as of 2026-07-31 | +3.5% | n/a | |
| Beta as of 2026-07-31 | 1.84 | 1.36 | |
| 1-year return as of 2026-07-27 close | -30.7% | +7.1% | OMDA higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.